Bryn Mawr Trust Advisors LLC Buys 2,881 Shares of Danaher Corporation $DHR

Bryn Mawr Trust Advisors LLC boosted its stake in Danaher Corporation (NYSE:DHR) by 3.8% during the second quarter, Holdings Channel.com reports. The firm owned 77,837 shares of the conglomerate’s stock after buying an additional 2,881 shares during the period. Danaher accounts for about 0.8% of Bryn Mawr Trust Advisors LLC’s portfolio, making the stock its 25th largest position. Bryn Mawr Trust Advisors LLC’s holdings in Danaher were worth $15,376,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Red Tortoise LLC raised its holdings in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock valued at $30,000 after buying an additional 98 shares during the last quarter. Ramirez Asset Management Inc. purchased a new position in shares of Danaher in the second quarter valued at about $40,000. Costello Asset Management INC purchased a new position in shares of Danaher in the first quarter valued at about $41,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of Danaher by 53.8% during the first quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock valued at $42,000 after acquiring an additional 71 shares during the last quarter. Finally, Iron Horse Wealth Management LLC purchased a new stake in shares of Danaher during the first quarter worth about $50,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 11.10% of the stock is currently owned by company insiders.

Danaher Price Performance

DHR opened at $210.97 on Friday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The company has a market cap of $149.02 billion, a price-to-earnings ratio of 43.50, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The stock has a fifty day simple moving average of $203.94 and a two-hundred day simple moving average of $200.14.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same period last year, the business earned $1.71 EPS. Danaher’s quarterly revenue was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is presently 26.39%.

Analysts Set New Price Targets

A number of research analysts recently issued reports on DHR shares. JPMorgan Chase & Co. boosted their price target on Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Cowen reaffirmed a “buy” rating on shares of Danaher in a research note on Wednesday, October 22nd. Robert W. Baird set a $247.00 price target on shares of Danaher in a report on Wednesday, October 22nd. Finally, UBS Group decreased their price objective on shares of Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $243.39.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.